Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AG Buyback Yield % Related Terms
Heidelberg Pharma AG Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:HPHA vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG (WBO:HPHA) has a Buyback Yield % of 0.00 as of Jul. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Heidelberg Pharma AG and its competitors. According to the industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 740 companies in the Biotechnology industry.
Is Heidelberg Pharma AG's Buyback Yield % too high?
Heidelberg Pharma AG's current Buyback Yield % is 0.00. Based on the distribution chart, Heidelberg Pharma AG ranks #999999 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 10/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 740 companies for Buyback Yield %. This places Heidelberg Pharma AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.87, compared to a current price of €2.55 — trading 11.1% below its estimated fair value. The current Buyback Yield % is 0.00. Heidelberg Pharma AG's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current Buyback Yield % is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued.
The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87.
GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.
Key valuation signals for WBO:HPHA:
Buyback Yield %: 0.00
GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
10GF Score
Get the complete analysis for WBO:HPHA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:HPHA has been successfully added to your 
